Medicair Group

What Medicair Group does

Medicair Group is a privately owned Greek pharmaceutical company, founded in 1998 and headquartered in Pallini, Athens, with manufacturing operations in Schimatari, Greece and a satellite office in Limassol, Cyprus. The legal operating entity is Medicair Bioscience Laboratories Ltd, registered in Cyprus. The company operates a vertically integrated model spanning formulation development, EU cGMP-compliant manufacturing, and commercialization, producing 80 branded generic pharmaceutical products alongside food supplements, medical devices, and cosmetics under proprietary brands such as VITAMINAir, DELOUSIL, SUNCAIR, FEETCAIR, MANDOO, MELOVIX, and ELBA. Its manufacturing capability covers pMDI (Metered-Dose Inhaler) canisters — at a stated annual capacity of 8 million units — as well as nasal sprays, tablets, capsules, oral liquids, semi-solids, foam sprays, and unit dose ampules, with 7% of turnover reinvested in R&D and 10+ new product developments per year.

Medicair derives revenue from four streams: (i) branded generic pharmaceutical and consumer health product sales, (ii) contract manufacturing for third-party pharmaceutical companies, (iii) product development services, and (iv) distribution and marketing services — both inbound (representing multinationals in the Greek market) and outbound (licensing and distributing its own branded generics internationally). Go-to-market in Greece is a 60-person direct sales force covering 15,000+ doctors and 4,000+ pharmacies daily; internationally, the company operates through distributor and licensing partnerships in 40+ countries, with products under registration in 90+ countries. The company is privately held with no disclosed parent, institutional investors, or M&A activity, and its governance and ownership are described as founder/management-owned.

Name

Medicair Group

Legal name

Medicair Bioscience Laboratories Ltd

Website

https://medicairgroup.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

Medicair Group is a privately held Greek pharmaceutical company that develops, manufactures, and distributes branded generics, food supplements, medical devices, and cosmetics, serving doctors, pharmacies, and international partners across 40+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Medical devices
• Contract manufacturing
• Food supplements
• Pharmaceutical distribution

Headquarters

HQ city

Athens

HQ country

Greece

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Sale of branded generic pharmaceutical products across multiple therapeutic areas including inhalers, tablets, capsules, oral liquids, semi-solids, and sprays. Portfolio covers all major therapeutic areas including allergology, pulmonology, cardiology, diabetology, gastroenterology, CNS, dermatology, and oncology.
2. Contract Manufacturing Services: Bespoke contract manufacturing solutions for pharmaceutical companies. Facilities handle large-scale and small-scale projects with efficiency and consistency. Manufacturing products in solid, semi-solid, and liquid form, OTCs and food supplements.
3. Product Development Services: Pharmaceutical product development services including formulation, regulatory compliance, quality testing, and registration support for clients seeking manufacturing partners.
4. Distribution Services in Greece: Marketing and distribution services provided to international companies launching products in the Greek market. Medical and pharmacy representatives cover the whole of Greece visiting doctors and pharmacies.
5. International Distribution: Licensing of proprietary developments and distribution of branded medicines through international partnerships and distributors across 40+ countries.
6. Medical Devices Sales: Sale of medical devices including Medistus Antivirus, CRYOPLEX-T Freeze spray, and TRAUMAPLEX-T Plaster spray
7. Food Supplements Sales: Sale of dietary supplements, nutraceuticals and functional foods under VITAMINAir and DELOUSIL brands covering superfoods, sports nutrition, and health and wellbeing sectors

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Core offering

Medicair Group manufactures and distributes a portfolio of branded generic pharmaceutical products (including pMDI inhalers, nasal sprays, tablets, capsules, oral liquids, semi-solids, foam sprays, and unit dose ampoules), food supplements, medical devices, and cosmetics. The company also provides B2B contract manufacturing, product development, and pharmaceutical distribution services in Greece and across 40+ international markets through its EU cGMP-compliant facilities built in 2012.

Product overview

Medicair Group is a privately owned Greek pharmaceutical company with vertically integrated operations spanning development, manufacturing, and commercialization. The company operates across five distinct product categories: (1) Pharmaceuticals comprising branded generic products in inhalers/MDIs, nasal sprays, and oral formulations (tablets, capsules, oral solutions) covering therapeutic areas including allergology, pulmonology, cardiology, dermatology, CNS, oncology, and diabetology; (2) Food Supplements under VITAMINAir, DELOUSIL, MELOVIX, and MANDOO brands including vitamin D3 products, B12 supplements, collagen and hyaluronic acid products, herbal supplements, and specialty formulations; (3) Medical Devices including Medistus Antivirus, CRYOPLEX-T Freeze spray, and TRAUMAPLEX-T Plaster spray; (4) Cosmetics under SUNCAIR, DELOUSIL, ELBA, and FEETCAIR brands including sunscreen, after-sun, skincare serums, mouthwashes, and foot care products; and (5) B2B services including contract manufacturing (specializing in pMDI inhalers with 8 million canister capacity), product development (GMP-compliant), and distribution services in Greece (60-person sales team) and internationally (40+ countries). The company has manufacturing facilities constructed in 2012 and has been operational since 1998.

Differentiator

Problem solved

Functional benefit

Brands

• VITAMINAir: Food supplements product line including vitamins, minerals and dietary supplements.
• DELOUSIL
• SUNCAIR
• FEETCAIR
• MELOVIX
• ELBA
• MANDOO
• Medistus
• CRYOPLEX-T
• TRAUMAPLEX-T

Products and services

• Pharmaceutical Inhalers (pMDI)

Quantifiable outcome

• 8 million canisters annual production capacity for pMDI inhalers
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Help Pharmaceuticals: Greek pharmaceutical company producing generics and specialty pharmaceutical products in multiple dosage forms. Directly comparable in size, market positioning, and product breadth.
• DEMO SA: Greek pharmaceutical manufacturer specializing in injectables and hospital pharmaceuticals with international exports. Comparable vertically integrated Greek pharma with strong export presence in tenders.
• Pharmathen: Greek-headquartered specialty generics manufacturer with strong international presence and complex generic formulations. Closest comparable by geography, business model (vertically integrated generics + international licensing), and therapeutic breadth.
• Hovione: Specialty CDMO with deep inhalation and respiratory product expertise. Direct comparable on the contract manufacturing and pMDI capability dimension Medicair emphasizes, relevant as both peer and potential competitor for outsourced inhalation work.
• Uni-Pharma: Greek pharmaceutical manufacturer with generic and injectable portfolio plus international distribution. Compares on Greek footprint, multi-dosage capability, and export orientation.
• Elpen Pharmaceutical: Greek pharmaceutical manufacturer with similar mid-size profile, generic focus, and domestic market presence. Comparable vertically integrated model with branded generics, R&D, and contracted manufacturing.
• Vianex: One of the largest Greek pharmaceutical manufacturers with branded generics and extensive product portfolio. Direct domestic peer in branded generics across major therapeutic areas.

Broad incumbents

• Stada Arzneimittel: European-focused generics and consumer healthcare group with multi-therapeutic portfolio and consumer health brands. Comparable diversified model spanning generics, branded generics, OTC, and consumer health across European and international markets.
• Sandoz: Novartis spin-off and global generics leader with strong European and respiratory portfolios. Comparable in generics breadth and inhalation exposure, particularly relevant as a CDMO/customer counterpart.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer. Operates broadly across the same generics/inhalation categories as Medicair but at vastly greater scale, defining the competitive pricing environment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicair Group